May 2006
Volume 47, Issue 13
ARVO Annual Meeting Abstract  |   May 2006
Use of Vitrase® for Vitreous Hemorrhage in Non–Surgical Candidates
Author Affiliations & Notes
  • R.M. Lieberman
    Retina Associates of New York, New York, NY
  • C. Zatezalo
    Mt. Sinai School of Medicine, New York, NY
  • Footnotes
    Commercial Relationships  R.M. Lieberman, ISTA Pharmaceuticals, C; ISTA Pharmaceuticals, R; C. Zatezalo, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 1446. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.M. Lieberman, C. Zatezalo; Use of Vitrase® for Vitreous Hemorrhage in Non–Surgical Candidates . Invest. Ophthalmol. Vis. Sci. 2006;47(13):1446.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Many patients with vitreous hemorrhage (VH) would benefit from surgical intervention (PPV), but for various reasons, are not surgical candidates. We assessed the efficacy of Vitrase® (highly purified ovine hyaluronidase) for clearing vitreous hemorrhage in these patients.

Methods: : 10 patients (10 eyes) with VH, who were non candidates for surgical intervention were treated with a single intravitreal injection of Vitrase®. The following parameters were evaluated: visual acuity (at multiple time points), ability of examiner to evaluate the retina and place appropriate therapy, complications, and patient satisfaction.

Results: : Eight (8) eyes received treatment with intravitreal Vitrase®. The ages ranged from 31–79 yr, with a 5:3 male–female ratio. Etiology for VH included diabetic retinopathy (6), venous occlusive disease (1) and sickle cell retinopathy (1). Etiologies for inclusion (definition: non–surgical candidate) were poor health, psychiatric illness, and patient unwillingness to have surgery. Follow up ranged from 3–6 months. All VH had been present at least 1 month (range 1 month to >6 months). At presentation, all visual acuities were off the chart [count fingers(CF) or worse]. At 2 weeks, 2 patients had achieved 20/50 or better, and another 2 were ≥ 20/200. At one month, 5 were ≥ 20/100. Six patients achieved ≥ 20/400 at 3 months, with three ≥20/50, and two ≥ 20/200. Two patients remained CF or HM for the duration of their follow up. Interestingly, of the 3 patients who quickly achieved 20/50 or better (within 2–4 weeks), all had a vitreous hemorrhage duration of less than 6 weeks. Of the 3 patients having VH duration ≥3 months, only 1 achieved any increase in VA. Improvement in VA correlated with ability to evaluate retina and place appropriate therapy. There were no visually significant complications. In addition,100% of patients stated they would repeat the procedure, if necessary.

Conclusions: : Vitrase® can be successfully used as an alternative to pars plana vitrectomy in patients with vitreous hemorrhage who are not surgical candidates. Patients with vitreous hemorrhage duration of less than 6 weeks had a more rapid and significant improvement of VA, in addition to the ability treat the underlying etiology of the VH. A majority of patients expressed satisfaction with the procedure.

Keywords: injection • diabetic retinopathy • quality of life 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.